Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis

Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: A real‐world intention‐to‐treat analysis

Brexucabtagene autoleucel (brexu‐cel) is an autologous CD19 CAR T‐cell product, approved for relapsed/refractory (r/r) mantle cell lymphoma (MCL). In ZUMA‐2, brexu‐cel demonstrated impressive responses in patients failing ≥2 lines, including a bruton's tyrosine kinase inhibitor, with an overall...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: O'Reilly, MA, Wilson, W, Burns, D, Kuhnl, A, Seymour, F, Uttenthal, B, Besley, C, Alajangi, R, Creasey, T, Paneesha, S, Elliot, J, Gonzalez Arias, C, Iyengar, S, Wilson, MR, Delaney, A, Rubio, L, Lambert, J, Begg, K, Boyle, S, Cheok, KPL, Collins, GP, Roddie, C, Johnson, R, Sanderson, R
التنسيق: Journal article
اللغة:English
منشور في: Wiley Open Access 2024

مواد مشابهة